PY265 / Ikena Oncology, Foundery Biosciences - LARVOL DELTA

Foundery Immune Studio, LLC Acquires Rights to a Suite of Next-Generation Clinical Stage Immunotherapies (PRNewswire) - " Foundery Immune Studio, LLC...announced today its acquisition of worldwide rights for three clinical-stage immune tuning therapies from Ikena Oncology, Inc...Antibodies PY314 and PY159, targeting TREM2 and TREM1, respectively, completed Phase 1 trials and were well tolerated. Both antibodies demonstrated promising pharmacodynamic effects alone and in combination with pembrolizumab. The third program targeting MARCO, PY265, is Investigational New Drug (IND)-ready."

Commercial • Non Small Cell Lung Cancer • Ovarian Cancer

Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement (Businesswire) - "Pionyr Immunotherapeutics, Inc...announced that Pionyr and Gilead Sciences, Inc...have mutually agreed to change their 2020 exclusive option agreements....As part of this agreement, Gilead waives its exclusive option to acquire Pionyr. Pionyr will be responsible for ongoing development of its pipeline, which includes PY159, PY314 and PY265. The company has the resources to advance its pipeline for the next two years. Within that timeframe, Pionyr will continue enrollment in Phase 1b expansion cohorts for both PY159 and PY314 in the refractory setting and is planning to add new frontline cohorts for both candidates. Pionyr has also completed IND-enabling studies for PY265 and will be ready to file an IND for that program in 2023."

IND • Licensing / partnership • Trial status • Oncology • Solid Tumor

Therapeutic targeting of MARCO with PY265 antibody promotes myeloid cell reprogramming and unleashes anti-tumor immunity (SITC 2022) - "Collectively, these preclinical data support PY265 immunotherapy, alone or in combination with a CPI, in cancer patients resistant or refractory to CPI therapies, to potentially improve both the overall response rate as well as durability of response. First-in-human testing of PY265 will be initiated in 2023."

IO biomarker • Oncology • Solid Tumor

Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022 (Businesswire) - "Pionyr plans to submit an IND for PY265 in 2023....Pionyr Immunotherapeutics, Inc...will present pre-clinical data showing the potential for its PY265 program to treat solid tumors, as a single agent and in combination with checkpoint inhibitor (CPI) therapy....In mice, a murine version of PY265 demonstrated significant anti-tumor activity—as a single agent in CPI-sensitive tumor models and in combination with anti-PD-1 in CPI-resistant tumor models. In a non-human primate toxicokinetic study, PY265 was generally well tolerated at all dose levels tested."

IND • Preclinical • Oncology • Solid Tumor